DC
MDNA

Davenport & Co’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Davenport & Co’s Portfolio MDNA Stock Details MDNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-27,750
Closed -$77K – 1129
2021
Q3 		$77K Buy
27,750
+2,600
+10% +$6.44K ﹤0.01% 1009
2021
Q2 		$76K Buy
+25,150
New +$93K ﹤0.01% 928

Other funds holding MDNA

ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
IIM
Intact Investment Management Montreal, Quebec, Canada $3.52B AUM 37.29% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
LBA
Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return

Davenport & Co's MDNA Position: Q4 2021 in Review

Davenport & Co sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q4 2021, closing a stake of 27,750 shares — an estimated $77K sold.

Davenport & Co first reported a position in MDNA in Q2 2021 and held it in 2 quarters. The position peaked at $77K in Q3 2021. 23 funds tracked by Wall St. Rank hold MDNA as of Q4 2021.

  • Davenport & Co reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q4 2021 after selling out during the quarter.
  • Davenport & Co sold 27,750 Medicenna Therapeutics Corp. Common Shares shares in Q4 2021, an estimated $77K.
  • Davenport & Co first reported a position in Medicenna Therapeutics Corp. Common Shares in Q2 2021 and held it in 2 quarters.
  • Davenport & Co's Medicenna Therapeutics Corp. Common Shares position peaked at $77K in Q3 2021.
  • 23 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q4 2021.

Based on Davenport & Co's 13F filing for Q4 2021, filed 10 Feb 2022.